Clinical implications of the p53 gene.

The capacity for malignant growth is acquired by the stepwise accumulation of defects in specific genes regulating cell growth and tissue homeostasis. Although several hundred genes are known to control growth, molecular genetic studies in cancer show that few of these are consistently involved in the natural history of human cancer, and those typically in only certain types of malignancy. Prospects for development of molecular-based diagnostic and therapeutic strategies with widespread application did not look promising, until it was realized that the p53 tumor suppressor gene was defective in approximately half of all malignancies. This discovery generated research efforts of unparalleled intensity to determine how p53 functions at the molecular level, and how to apply this knowledge to clinical ends.

[1]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[2]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[3]  Y. Nakamura,et al.  Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. , 1989, JAMA.

[4]  M. Barbosa,et al.  The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. , 1989, Oncogene.

[5]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[6]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[7]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[8]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[9]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[10]  P. Howley,et al.  Role of the human papillomaviruses in human cancer. , 1991, Cancer research.

[11]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[12]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[14]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[16]  J. Minna,et al.  Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.

[17]  D. Wynford‐Thomas P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[18]  R. Knapp,et al.  Unifocal origin of advanced human epithelial ovarian cancers. , 1992, Cancer research.

[19]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[20]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[21]  J. Marks,et al.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[23]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[24]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[25]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[26]  W. Hong,et al.  Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. , 1993, Cancer research.

[27]  R. Hruban,et al.  The incidence of p53 mutations increases with progression of head and neck cancer. , 1993, Cancer research.

[28]  D. Brachman,et al.  p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. , 1993, Cancer research.

[29]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[30]  Kathleen R. Cho,et al.  Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Minna,et al.  Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. , 1993, Journal of the National Cancer Institute.

[32]  P. Meltzer,et al.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas. , 1993, Cancer research.

[33]  P. Hainaut,et al.  Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. , 1993, Cancer research.

[34]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[35]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[36]  T. Mitsudomi,et al.  Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[37]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[38]  P. Laurent-Puig,et al.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.

[39]  J. Berzofsky,et al.  Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. , 1994, Cancer research.

[40]  M. Asada,et al.  Clonal expansion of p53 mutant cells in leukemia progression in vitro. , 1994, Leukemia.

[41]  J. Roth,et al.  Posttranslational regulation of p53 tumor suppressor protein function. , 1994, Critical reviews in oncogenesis.

[42]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[43]  R. Hruban,et al.  Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.

[44]  C. Prives How loops, β sheets, and α helices help us to understand p53 , 1994, Cell.

[45]  B. Vogelstein,et al.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms , 1994, The Journal of pathology.

[46]  D. Malkin,et al.  Germline p53 mutations and heritable cancer. , 1994, Annual review of genetics.

[47]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[48]  D. Fisher Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[49]  D. Givol,et al.  Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.

[50]  B. Vogelstein,et al.  Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Stephen J. Elledge,et al.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest , 1994, Cell.

[52]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[53]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[54]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[55]  M. Espié,et al.  p53 mutations and overexpression in locally advanced breast cancers. , 1994, British Journal of Cancer.

[56]  R. Hruban,et al.  Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. , 1994, The New England journal of medicine.

[57]  C. Cordon-Cardo,et al.  p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Elledge,et al.  Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[59]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[60]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[61]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[62]  E. Diamandis,et al.  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers , 1994, International journal of cancer.

[63]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[64]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[65]  M. Evans,et al.  p53 modulation of TFIIH–associated nucleotide excision repair activity , 1995, Nature Genetics.

[66]  R H Hruban,et al.  Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[67]  H. Steller Mechanisms and genes of cellular suicide , 1995, Science.

[68]  C. Prives,et al.  Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus , 1995, Cell.

[69]  R H Hruban,et al.  Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[70]  P. Chappuis,et al.  A simple p53 functional assay for screening cell lines, blood, and tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[71]  D. Sidransky Molecular markers in cancer diagnosis. , 1995, Journal of the National Cancer Institute. Monographs.

[72]  M. Ewen,et al.  The transcription factor E2F-1 is a downstream target of RB action , 1995, Molecular and cellular biology.

[73]  S. Elledge,et al.  p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells , 1995, Science.

[74]  A. Levine,et al.  p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches , 1995, Cell.

[75]  M. Dean Resolving DNA mutations , 1995, Nature Genetics.

[76]  L. Norton,et al.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  G. Stark,et al.  p53-dependent growth arrest of REF52 cells containing newly amplified DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[78]  D. Lane,et al.  The dominating effect of mutant p53 , 1995, Nature Genetics.

[79]  K. Kinzler,et al.  p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. , 1995, Genes & development.

[80]  T. Soussi,et al.  Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.

[81]  J. Bonneterre,et al.  Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer , 1995, The Lancet.

[82]  M. Kirschner,et al.  Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA , 1995, Nature.

[83]  C. Harris,et al.  Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. , 1995, Journal of the National Cancer Institute.

[84]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[85]  Lawrence A. Donehower,et al.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice , 1995, Nature Genetics.

[86]  N. Rainov,et al.  Absence of p53 autoantibodies in sera from glioma patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.